Placeholder Banner

BIO's 2019 Special 301 Submission

March 27, 2019

Section 182 of the Trade Act of 1974, known as the “Special 301” provisions, requires the United States Trade Representative to identify countries that deny adequate and effective intellectual property protections or fair and equitable market access to U.S. persons who rely on IP protection. As part of the 2019 Special 301 Review process conducted by USTR, Justin Pine prepared BIO’s formal submission and presented oral testimony to USTR and the interagency Special 301 subcommittee highlighting the IP issues facing our members in key markets around the world.

The principal concerns highlighted in BIO’s submission are: i) global compulsory licensing trends; ii) lack of adequate or any regulatory data protection; iii) restrictive patentability frameworks; and iv) market access concerns associated with drug pricing controls. 

Download Full Comments Below
BIO 2019 Special 301 Review Comment
2019 SPECIAL 301 SUBMISSION
Discover More
BIO urges the Administration to fully assess the potential impact of export controls on biotechnologies on “the impact on the economy of the United States” and on the sustainability of the U.S.’s global leadership in biotechnology, and pursue them …
BIO greatly appreciates efforts from Congress to mitigate the current economic crisis for employers, employees, and all our families. In recent days, we have been asked by several of your colleagues for policy ideas that could assist with…
On behalf of the Biotechnology Innovation Organization (BIO), thank you for the opportunity to provide comments to the United States Department of Agriculture on its June 6, 2019 Proposed Rule regarding the movement of certain genetically engineered…